KRTX News and Press, Karuna Therapeutics Inc. From 12/26/22

Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...

Summary Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercialization partnerships with foreign entities. Also, the in-house pipeline is set t...

Summary Karuna Therapeutics, Inc. transitioned a new CEO in yesterday, with the former chief now president of R&D. Questions now arise on Karuna Therapeutics' suitability as a takeover candidate. Data and momentum is compounding for Karuna Therapeutics' KarXT investigational lab...

Clinical-stage biotech Karuna Therapeutics ( NASDAQ: KRTX ) shed ~12% on Tuesday after naming former Allergan executive Bill Meury as president, chief executive officer, and board member, effective Jan. 03, 2023. Steve Paul, who currently serves as the president, CEO, and chairman...

Mr. Meury is a distinguished pharmaceutical leader with more than 25 years of operational and commercial experience delivering transformative medicines to patients Succeeds current president, chief executive officer, and chairman, Steve Paul, M.D., who will transition to president of research...

Summary Neurocrine announced another better-than-expected quarter for Ingrezza, as enhanced sales efforts are driving reacceleration in sales. The company will be announcing Phase II results from multiple programs over the next year, and while these are high-risk programs, success...

Karuna Therapeutics press release ( NASDAQ: KRTX ): Q3 GAAP EPS of -$2.38 misses by $0.27 . The Company ended the quarter with $1.2 billion in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as of December 31, 2021. The in...

Initiated the Phase 3 ADEPT-1 trial of KarXT in Alzheimer’s disease psychosis in the third quarter of 2022 Phase 3 EMERGENT-3 trial completed enrollment in the fourth quarter of 2022, with topline data anticipated in the first quarter of 2023 On track to submit ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Troy Ignelzi, chief financial officer of Karuna Therapeutics, w...

Summary Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of man...